Company intelligence / Profile preview

Topelia Therapeutics

Rehovot, Israel

Ownership: Private
Development stage: Other

Overview

Topelia Therapeutics is a biotechnology company dedicated to developing precision medicines for infectious diseases by targeting the microbiome. The company's lead candidate, TOP-101, is designed to specifically eliminate Clostridioides difficile while preserving the healthy gut flora, addressing a significant unmet need in recurrent infections. Utilizing its proprietary precision antimicrobial platform, Topelia aims to create a new class of narrow-spectrum therapies that avoid the pitfalls of broad-spectrum antibiotics. The company is headquartered in Israel and focuses on transforming the treatment landscape for hospital-acquired infections and microbiome-related disorders.

Therapeutic areas: Infectious Diseases
Modalities: Live biotherapeutic product therapyTargeted antimicrobial
Industry: Biotech

Beyond the preview

Go deeper on Topelia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Topelia Therapeutics.

Explore the full profile